Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Iressa gefitinib: Phase II data; FDA approved for non-small cell lung cancer (NSCLC)

In a U.S. Phase II trial in 51 patients who

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE